KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Long-Term Deferred Tax (2009 - 2019)

Bio-Rad Laboratories (BIO) reported Long-Term Deferred Tax of $138.0 million for Q4 2019, up 80.87% year-over-year from $76.3 million in Q4 2018, and up 80.87% on a QoQ basis from $76.3 million in Q4 2018.

Bio-Rad Laboratories (BIO) has 11 years of Long-Term Deferred Tax data on file, last reported at $138.0 million in Q4 2019.

  • Quarterly Long-Term Deferred Tax rose 80.87% year-over-year to $138.0 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $138.0 million (up 80.87% YoY) and the FY2019 annual result came in at $138.0 million, up 80.87% from the prior year.
  • Long-Term Deferred Tax advanced to $138.0 million in Q4 2019 per BIO's latest filing, from $76.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $138.0 million in Q4 2019 and bottomed at $76.3 million in Q4 2018.
  • The 5-year median for Long-Term Deferred Tax is $99.5 million (2015), against an average of $102.2 million.
  • The widest annual swing landed in 2017, when Long-Term Deferred Tax slumped 32.77%; it then soared 80.87% in 2019.
  • Tracing BIO's Long-Term Deferred Tax over 5 years: stood at $99.5 million in 2015, then advanced by 18.39% to $117.8 million in 2016, then tumbled by 32.77% to $79.2 million in 2017, then fell by 3.66% to $76.3 million in 2018, then jumped by 80.87% to $138.0 million in 2019.
  • Per Business Quant, the three latest BIO Long-Term Deferred Tax figures stand at $138.0 million (Q4 2019), $76.3 million (Q4 2018), and $79.2 million (Q4 2017).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Bio-Rad Laboratories 8.23 Bn 6.66 Bn 309.40 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 138.00 Mn
Dec 31, 2018 76.30 Mn
Dec 31, 2017 79.20 Mn
Dec 31, 2016 117.80 Mn
Dec 31, 2015 99.50 Mn
Dec 31, 2014 81.20 Mn
Dec 31, 2013 79.00 Mn
Dec 31, 2012 78.10 Mn
Dec 31, 2011 11.19 Mn
Dec 31, 2010 54.20 Mn
Dec 31, 2009 13.27 Mn